GPR43 Activation-mediated Lipotoxicity Contributes to Podocyte Injury in Diabetic Nephropathy by Modulating the ERK/EGR1 Pathway
Overview
Authors
Affiliations
G-protein-coupled receptor 43 (GPR43) is a posttranscriptional regulator involved in cholesterol metabolism. This study aimed to investigate the possible roles of GPR43 activation in podocyte lipotoxicity in diabetic nephropathy (DN) and explore the potential mechanisms. The experiments were conducted by using diabetic GPR43-knockout mice and a podocyte cell culture model. Lipid deposition and free cholesterol levels in kidney tissues were measured by BODIPY staining and quantitative cholesterol assays, respectively. The protein expression of GPR43, LC3II, p62, beclin1, low-density lipoprotein receptor (LDLR) and early growth response protein 1 (EGR1) in kidney tissues and podocytes was measured by real-time PCR, immunofluorescent staining and Western blotting. There were increased LDL cholesterol levels in plasma and cholesterol accumulation in the kidneys of diabetic mice. However, GPR43 gene knockout inhibited these changes. An study further demonstrated that acetate treatment induced cholesterol accumulation in high glucose-stimulated podocytes, which was correlated with increased cholesterol uptake mediated by LDLR and reduced cholesterol autophagic degradation, as characterized by the inhibition of LC3 maturation, p62 degradation and autophagosome formation. Gene knockdown or pharmacological inhibition of GPR43 prevented these effects on podocytes. Furthermore, GPR43 activation increased extracellular regulated protein kinases 1/2 (ERK1/2) activity and EGR1 expression in podocytes, which resulted in an increase in cholesterol influx and autophagy inhibition. In contrast, after GPR43 deletion, these changes in podocytes were improved, as shown by the and results. GPR43 activation-mediated lipotoxicity contributes to podocyte injury in DN by modulating the ERK/EGR1 pathway.
Autophagy and Mitophagy in Diabetic Kidney Disease-A Literature Review.
Stanigut A, Tuta L, Pana C, Alexandrescu L, Suceveanu A, Blebea N Int J Mol Sci. 2025; 26(2).
PMID: 39859520 PMC: 11766107. DOI: 10.3390/ijms26020806.
Wu W, Wang Y, Shao X, Huang S, Wang J, Zhou S PLoS One. 2024; 19(12):e0314628.
PMID: 39621727 PMC: 11611192. DOI: 10.1371/journal.pone.0314628.
Rao M, Nassiri V, Srivastava S, Yang A, Brar S, McDuffie E Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598459 PMC: 11597314. DOI: 10.3390/ph17111550.
Molecular mechanism of renal lipid accumulation in diabetic kidney disease.
Fang Z, Liu R, Xie J, He J J Cell Mol Med. 2024; 28(11):e18364.
PMID: 38837668 PMC: 11151220. DOI: 10.1111/jcmm.18364.
Early growth response 1 as a podocyte injury marker in human glomerular diseases.
Okabe M, Koike K, Yamamoto I, Tsuboi N, Matsusaka T, Yokoo T Clin Kidney J. 2024; 17(1):sfad289.
PMID: 38186896 PMC: 10768762. DOI: 10.1093/ckj/sfad289.